← Back to Search

Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Guangzhou, China
Phase 1
Waitlist Available
Research Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 to 504 hours
Awards & highlights
No Placebo-Only Group

Summary

To evaluate the safety and pharmacokinetics of single-dose HR20013 for injection combined with dexamethasone in patients with malignant solid tumors receiving cisplatin-based chemotherapy.

See full description
Eligible Conditions
  • Prevention of Nausea and Vomiting

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 to 504 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 to 504 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Therapeutic procedure

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: HR20013 for injection+dexamethasoneExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HR20013 for injection；dexamethason
2022
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

Fujian Shengdi Pharmaceutical Co., Ltd.Lead Sponsor
35 Previous Clinical Trials
6,037 Total Patients Enrolled
~7 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top